期刊
ACTA NEUROPATHOLOGICA
卷 129, 期 1, 页码 115-131出版社
SPRINGER
DOI: 10.1007/s00401-014-1352-5
关键词
Glioblastoma; Bevacizumab; Metabolism; Adaptation
资金
- Centre de Recherche Public de la Sante (CRP-Sante) through Ministry of Research and Higher Education in Luxembourg
- Centre de Recherche Public de la Sante (CRP-Sante) through Fonds National de la Recherche (FNR) of Luxembourg
- Norwegian Cancer Society
- Norwegian Research Council
- Innovest AS
- Helse Vest
- Haukeland University Hospital
- Bergen Medical Research Fund
- University of Bergen
- Kristian Gerhard Jebsen Foundation
- Cancer Research UK
- Cancer Research UK [18278] Funding Source: researchfish
Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing C-13(6)-glucose metabolic flux analysis, we show for the first time that the tumors undergo metabolic re-programming toward anaerobic metabolism, thereby uncoupling glycolysis from oxidative phosphorylation. Following treatment, an increased influx of C-13(6)-glucose was observed into the tumors, concomitant to increased lactate levels and a reduction of metabolites associated with the tricarboxylic acid cycle. This was confirmed by increased expression of glycolytic enzymes including pyruvate dehydrogenase kinase in the treated tumors. Interestingly, L-glutamine levels were also reduced. These results were further confirmed by the assessment of in vivo metabolic data obtained by magnetic resonance spectroscopy and positron emission tomography. Moreover, bevacizumab led to a depletion in glutathione levels indicating that the treatment caused oxidative stress in the tumors. Confirming the metabolic flux results, immunohistochemical analysis showed an up-regulation of lactate dehydrogenase in the bevacizumab-treated tumor core as well as in single tumor cells infiltrating the brain, which may explain the increased invasion observed after bevacizumab treatment. These observations were further validated in a panel of eight human GBM patients in which paired biopsy samples were obtained before and after bevacizumab treatment. Importantly, we show that the GBM adaptation to bevacizumab therapy is not mediated by clonal selection mechanisms, but represents an adaptive response to therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据